Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ: PHAT · IEX Real-Time Price · USD
10.14
-0.33 (-3.15%)
At close: Apr 12, 2024, 4:00 PM
9.86
-0.28 (-2.76%)
After-hours: Apr 12, 2024, 5:51 PM EDT
-3.15%
Market Cap 592.96M
Revenue (ttm) 682,000
Net Income (ttm) -201.59M
Shares Out 58.48M
EPS (ttm) -3.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 947,869
Open 10.54
Previous Close 10.47
Day's Range 9.97 - 11.20
52-Week Range 6.07 - 17.02
Beta 0.63
Analysts Strong Buy
Price Target 21.33 (+110.36%)
Earnings Date May 8, 2024

About PHAT

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is head... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 452
Stock Exchange NASDAQ
Ticker Symbol PHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price forecast is $21.33, which is an increase of 110.36% from the latest price.

Price Target
$21.33
(110.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

10 days ago - GlobeNewsWire

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive...

18 days ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

5 weeks ago - GlobeNewsWire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J.

6 weeks ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

4 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA ta...

4 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

FLORHAM PARK, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

NEW YORK , Oct. 23, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary dut...

6 months ago - PRNewsWire

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

FLORHAM PARK, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

7 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

8 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

FLORHAM PARK, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

8 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

10 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

11 months ago - GlobeNewsWire

PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 9, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom Pharmaceuticals, I...

11 months ago - PRNewsWire

PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

NEW YORK , June 8, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) concerning possible viola...

11 months ago - PRNewsWire

PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

NEW YORK , May 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated federal securities laws...

11 months ago - PRNewsWire

PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws

NEW YORK , May 31, 2023 /PRNewswire/ -- Attention Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced in...

11 months ago - PRNewsWire

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...

11 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...

11 months ago - GlobeNewsWire

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe...

11 months ago - GlobeNewsWire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , May 22, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceutica...

11 months ago - PRNewsWire